Non-Stimulant ADHD NDA Resubmitted; Schizophrenia or Viral Encephalitis?

(MedPage Today) -- Supernus Pharmaceuticals resubmitted its FDA marketing application for SPN-812, a non-stimulant attention-deficit/hyperactivity disorder (ADHD) treatment for children based on viloxazine hydrochloride.
Emergency department visits...